Last reviewed · How we verify

NCT06281054

Acute Myocardial Infarction in Cancer Patients

Active, enrolled Last updated 14 March 2025
What this trial tests

trial testing Revascularization in Acute Myocardial Infarction in 4,500,000 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 January 2002
Primary endpoint
31 December 2021
31 December 2025

Quick facts

Lead sponsorSamsung Medical Center
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment4,500,000
Start date1 January 2002
Primary completion31 December 2021
Estimated completion31 December 2025
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Samsung Medical Center

Who can join

Eligibility, any sex, with Acute Myocardial Infarction or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Using national health insurance service database, current study aim to evaluate the risk and prognosis of acute myocardial infarction in cancer patients and to find the optimal treatment strategy for acute myocardial infarction that can improve long-term prognosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Revascularization

Trials testing the same drug.

Other recruiting trials for Acute Myocardial Infarction

Currently open trials in the same condition.

Other Samsung Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06281054.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing